Collaboration Agreements - Additional Information (Details)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 30, 2021 USD ($)	Aug. 31, 2020 USD ($) Program	Oct. 31, 2018 Program	Jun. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from fees received						$ 6,000,000.0
Accounts receivable current, research extension fee						2,000,000.0
Contract asset, research extension fee						4,000,000.0
Receivable research extension fee						12,000,000.0
2018 Gilead Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research term			3 years
Number of licensed product | Program			5
Non-refundable upfront payment received						50,000,000.0		$ 50,000,000.0
Milestone payments receivable								$ 1,700,000,000
Amended Gilead Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research term		7 years
Number of licensed product | Program		15
Non-refundable upfront payment received						125,000,000.0
Milestone payments receivable		$ 410,000,000.0
Temporary equity, par value		125,000,000.0
Revenue recognized, cumulative catch-up adjustment					$ (11,300,000)
Research extension fee										$ 12,000,000.0	$ 12,000,000.0
Research extension fees, variable consideration						$ 12,000,000.0
Contract with customer liability, revenue recognized				$ 11,000,000.0
License fee amount	$ 11,000,000.0
Amended Gilead Agreement [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment, ownership percentage						10.00%
Amended Gilead Agreement [Member] | Series B-1 Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Temporary equity, par value		$ 20,000,000.0
Gilead Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transaction price allocated to performance obligation						$ 199,000,000.0
Short-term deferred revenue						28,200,000			$ 26,000,000.0
Long-term deferred revenue						105,000,000.0			$ 114,700,000
Collaboration Revenue [Member] | Gilead Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer liability, revenue recognized						$ 11,500,000	$ 13,500,000